中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (2): 128-134.doi: 10.3969/j.issn.1007-3969.2014.02.008

• 论著 • 上一篇    下一篇

18F-FES在乳腺癌患者体内摄取与病理免疫组化的关系

孙艺斐1,杨忠毅1,张勇平1,王明伟1,姚之丰1,薛静1,鲍晓1,杨文涛2,沈镇宙3,邵志敏3,章英剑1   

  1. 1.复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海 200032;
    2.复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032;
    3.复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2014-02-28 发布日期:2014-03-07
  • 通信作者: 章英剑 E-mail:yjzhang111@aliyun.com

The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

SUN Yi-fei1,YANG Zhong-yi1,ZHANG Yong-ping1,WANG Ming-wei1,YAO Zhi-feng1,XUE Jing1,BAO Xiao1,YANG Wen-tao2,SHEN Zhen-zhou3,SHAO Zhi-min3,ZHANG Ying-jian1   

  1. 1.Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
    2. Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
    3. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2014-02-28 Online:2014-03-07
  • Contact: ZHANG Ying-jian E-mail: yjzhang111@aliyun.com

摘要:

背景与目的:16α-18F-17β-雌二醇(18F-FES)作为雌激素受体(estrogen receptor, ER)特异性显像剂,可在活体内反映ER的表达状况。本研究主要探讨乳腺癌患者体内18F-FES摄取结果与病理免疫组化的相关性。方法:自行制备18F-FES,入组26例乳腺癌患者(17例原发性乳腺癌,9例复发转移性乳腺癌),分别进行18F-FES18F-FDG PET/CT显像,对每例患者进行空心针穿刺或手术治疗,对比相应病灶的免疫组化和18F-FES18F-FDG摄取结果。结果:96.15%(25/26)的患者18F-FES结果与ER病理免疫组化一致,以18F-FES SUVmax1.5ER阳性,18F-FES PET/CT显像诊断乳腺癌病灶ER阳性的灵敏度为93.33%,特异度为100%ERPR的免疫组化结果与18F-FESSUVmax呈明显的正相关;HER-2/Neu的免疫组化结果与18F-FESSUVmax呈负相关。结论:18F-FES有望用于全面反映乳腺癌患者全身病灶的ER表达情况,为临床个体化治疗方案的制定提供帮助。

关键词: 雌激素受体, 免疫组化, 18F-FES, 18F-FDG, ER亚型

Abstract:

Background and purpose: 16α-[18F]fluoroestradiol (18F-FES) is an in vivo specific imaging agent for estrogen receptor (ER). We investigated the concordance between tumor ER status as determined by FES-PET and in vitro immunohistochemical assays. Methods: 18F-FES was prepared by ourselves. Twenty-six patients were enrolled (17 primary and 9 metastatic/recurrent). Patients underwent both 18F-FES and 18F-FDG PET/CT. Results: We found good overall agreement (96.15%) between in vitro ER assays and FES-PET. The ER status diagnosis sensitivity of 18F-FES was 93.33% and the specificity was 100% when using cut-off value of SUVmax1.5. There was a positive correlation between in vitro ER, PR assays and the SUVmax of 18F-FES while in vitro HER-2/neu assays correlatived negatively with 18F-FES SUVmax. Conclusion: These results suggested 18F-FES may be useful for studying the ER expression of all malignant lesions in patients with breast cancer and guiding individual therapy.

Key words: Estrogen receptor, Immunohistochemistry, 18F-FES, 18F-FDG, ER subtype